CJ-13,610

CAT: 0804-HY-106200-01Size: 5 mgDry Ice: NoHazardous: No

1 / 1

CAT#:0804-HY-106200-01Size:5 mg

Selected

24/48H Stock Items & 2 to 6 Weeks non Stock Items.

Quick Request Actions

Description

CJ-13,610, a nonredox-type 5-LO inhibitor, dose dependently suppresses 5-LO product formation in ionophore A23187-stimulated PMNL in the absence of exogenous AA with an IC50 of about 70 nM[1]. PMNL: polymorphonuclear leukocytes; AA: arachidonic acid

CAS Number

179420-17-8

UNSPSC

12352005

Target

Lipoxygenase

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/cj-13-610.html

Purity

98.10

Solubility

DMSO : 10 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

NC(C1(C2=CC(SC3=CC=C(N4C(C)=NC=C4)C=C3)=CC=C2)CCOCC1)=O

Molecular Formula

C22H23N3O2S

Molecular Weight

393.50

References & Citations

[1]Fischer L, et al. Molecular pharmacological profile of the nonredox-type 5-lipoxygenase inhibitor CJ-13,610. Br J Pharmacol. 2004;142 (5) :861-868.

Shipping Conditions

Room Temperature

Storage Conditions

-20°C, 3 years; 4°C, 2 years (Powder)

Scientific Category

Reference compound1

Clinical Information

Phase 2

Related Products

Catalog	Name
HY-10797-01	CJ-42794
HY-10050	CJ-17493
HY-13597	CJ-15161
HY-131909	CJ-2360
HY-117881	CJ-15208
HY-19182	CJ-12255
HY-123191	CJ-463
HY-N7188	CJ-21,058
HY-118474-01	GW 610
HY-D2042	ATTO 610

Alternative Products

Catalog	Name
T27026-01	CJ-13,610
MBS3616444-01	CJ-13,610 hydrochloride
C3640-1	CJ-023423
EHA42017-01	CJ-13610
T14975-01	CJ-42794
T69330-01	CJ-14897
T27027-01	CJ-15208
MBS3616203-01	CJ 033466
MBS5813739	CJ-887
sc-280646A	CJ-21058

CJ-13,610

Related Products

Alternative Products

Popular Products